Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: Racine and nonhuman primates

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8561-8576

  Yang, Wen Qing ^a   Lun, Xueqing ^a   Palmer, Cheryl Ann ^g   Wilcox, M Elizabeth ^b   Muzik, Huong ^a   Shi, Zhong Qiao ^a   Dyck, Richard ^e   Coffey, Matt ^h   Thompson, Brad ^h   Hamilton, Mark ^a   Nishikawa, Sandra G ^a   Brasher, Penny M A ^c   Fonseca, Kevin ^f   George, David ^a   Rewcastle, N Berry ^a   Johnston, Randal N ^a   Stewart, Doug ^a   Lee, Patrick W K ^d   Senger, Donna L ^a   Forsyth, Peter A ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^g University of Alabama at Birmingham   (United States)

^h ONCOLYTICS BIOTECH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; VIRUS RNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GLIOMA; GLIOMA CELL; GROWTH INHIBITION; HISTOPATHOLOGY; IMMUNIZATION; IN SITU HYBRIDIZATION; MAZE TEST; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; RAT; REOVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MODEL; VIRUS CULTURE; VIRUS INFECTION; WESTERN BLOTTING;

ANIMALS; BRAIN NEOPLASMS; ENCEPHALITIS; FEMALE; GLIOBLASTOMA; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOGLOBULIN G; IN SITU HYBRIDIZATION; MACACA FASCICULARIS; MALE; MAMMALIAN ORTHOREOVIRUS 3; MAZE LEARNING; MODELS, ANIMAL; NEUTRALIZATION TESTS; RATS; RATS, INBRED F344; RATS, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 19944427873     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0940     Document Type: Article

References (54)

1. Bell JC, Garson KA, Lichty DB, Stojdl DF. Onctolytic viruses: programmable tumour hunters. Curr Gene Ther 2002;2:243-54.
2. Gromeier M, Wimmer E. Viruses for the treatment of malignant glioma. Curr Opin Mol Ther 2001;3:503-8.
3. Norman KL, Farassati F, Lee PW. Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev 2001;12:271-82.
4. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science (Wash. DC) 1998;282:1332-4.
5. Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst (Bethesda) 2001;93:903-12.
6. Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002;62:1696-701.
7. Hirasawa K, Nishikawa SG, Norman KL, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003;63:348-53.
8. Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood 2002;100:4146-53.
9. Thirukkumaran CM, Luider JM, Stewart DA, et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003;102:377-87.
10. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002;13:641-52.
11. Etoh T, Himeno Y, Matsumoto T, et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003;9:1218-23.
12. Yang WQ, Senger D, Muzik H, et al. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res 2003;63:3162-72.
13. Yang WQ, Senger DL, Lun XQ, et al. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther 2004;11:1579-89.
14. Tyler K, Fields BN. Reoviruses. In: Fields, BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, editors. Virology, 3rd ed. Philadelphia: Lippincott-Raven; 1996. p. 1597-623.
15. Sherry B, Li XY, Tyler KL, Cullen JM, Virgin HW IV. Lymphocytes protect against and are not required for reovirus-induced myocarditis. J Virol 1993;67:6119-24.
16. Strong JE, Tang D, Lee PW. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology 1993;197:405-11.
17. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996;70:612-6.
18. Strong J, Coffey M, Tang D, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-62.
19. Yang M, Baranov E, Wang JW, et al. Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proc Natl Acad Sci USA 2002;99:3824-9.
20. Morris RGM, Garrud P, Rawlins JNP, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature (Lond.) 1982;297:681-3.
21. Walter EZ, Eric A, Jeffrey B, et al. Impaired spatial cognition and synaptic potentiation in a murine model of human immunodeficiency virus type 1 encephalitis. Exp Neurol 1992;116:122-32.
22. Thifault S, Lalonde R, Sanon N, Hamet P. Comparisons between C57BL/6J and A/J mice in motor activity and coordination, hole-poking, and spatial learning. Brain Res Bulletin 2001;58:213-8.
23. Sutherland RJ, Richard HD. Place navigation by rats in a swimming pool. Can J Psychol 1984;38:322-47.
24. Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999;73:6319-26.
25. Todo T, Feigenbaum F, Rabkin SD, et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000;2:588-95.
26. Raine CS, Fields BN. Reovirus type III encephalitis: a virologic and ultrastructural study. J Neuropathol Exp Neurol 1973;32:19-33.
27. Jackson GG, Muldoon RL. Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses. J Infect Dis 1973;128:811-33.
28. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5:881-7.
29. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998;5:121-30.
30. Miller CG, Fraser NW. Role of the immune response during neuroattenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res 2000;60:5714-22.
31. Park KH, Kim G, Jang SH, et al. Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer. Anticancer Res 2003;23:1559-64.
32. Barzon L, Bonaguro R, Castagliuolo I, et al. Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol 2003;148:73-80.
33. Bristol JA, Zhu M, Ji H, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003;7:755-64.
34. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999;5:1256-63.
35. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-75.
36. Nagayama Y, Nakao K, Mizuguchi H, et al. Enhanced antitumor effect of combined replicative adenovirus and nonreplicative adenovirus expressing interleukin-12 in an immunocompetent mouse model. Gene Ther 2003;10:1400-3.
37. Ebert O, Shinozaki K, Huang TG, et al. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003;63:3605-11.
38. Balachandran S, Barber GN. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 2000;50:135-8.
39. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994;54:5745-51.
40. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74). RT-2 and CNS-1 gliomas. J Neurooncol 1998;36:91-102.
41. Culver KW, Ram Z, Wallbridge S, et al. In vivo transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Wash. DC) 1992;256:1550-2.
42. Iwadate Y, Namba H, Tagawa M, et al. Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cells by the expression of herpes simplex virus-thymidine kinase gene and ganciclovir administration. Oncology 1997;54:329-34.
43. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998;16:444-8.
44. Kramm CM, Rainov NG, Sena-Esteves M, et al. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther 1996;7:291-300.
45. Kramm CM, Rainov NG, Sena-Esteves M, et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther 1996;7:1989-94.
46. Rainov NG, Kramm CM, Aboody-Guterman K, et al. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther 1996;3:99-106.
47. Tardieu M, Powers ML, Weiner HL. Age dependent susceptibility to reovirus type 3 encephalitis: role of viral and host factors. Ann Neurol 1983;13:602-7.
48. Matsumoto S, Isshiki A, Watanabe Y, Wieloch T. Restricted clinical efficacy of cyclosporin A on rat transient middle cerebral artery occlusion. Life Sci 2002;72:591-600.
49. Uchino H, Minamikawa-Tachino R, Kristian T, et al. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol Dis 2002;10:219-33.
50. Uchino H, Elmer E, Uchino K, et al. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Brain Res 1998;812:216-26.
51. Wakimoto H, Ikeda K, Chiocca EA. Immunosuppression with cyclophosphamide enhances cell-to-cell spread of replication conditional herpes simplex virus vector in immunocompetent rat gliosarcoma model. Neuro-Oncology 2001;3 (Suppl 1):s47.
52. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
53. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003;63:1317-24.
54. Morris D, Forsyth PA, Paterson AH, et al. A phase I clinical trial valuating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol Annu Meet 2002;21:92:24.